

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Cabotegravir injections for preventing HIV-1 in adults and young people [ID6255]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was noted that HIV disproportionately affects people of Black African family background. It was also noted that HIV is more prevalent in people of certain sexual orientation such as gay or bisexual men.

Lifestyle factors may affect people's ability to attend clinics or adhere to their medication. For example, people who are underserved (for example people who are homeless or who use drugs) may have difficulties adhering to daily oral medication because it needs to be taken at the same time each day, with food. Whereas long-acting injections may not suit people who cannot easily access their clinic for appointments. Long-acting injections may also benefit young people who may struggle with adhering to oral therapies.

Clinical trial evidence suggests that cabotegravir is more effective at preventing HIV than the standard of care in women, men who have sex with men and transgender women.

Cabotegravir will need to be administered in a healthcare setting. This may make it more difficult for people with a disability to access cabotegravir as they may find it more challenging to visit a healthcare setting in person.

People who are pregnant, planning to become pregnant or breastfeeding may not be able to receive cabotegravir as it has not been widely trailed in these populations.

--

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in this technology appraisal. The committee will consider whether there are any subgroups for whom the clinical and cost-effectiveness of cabotegravir is expected to be different. The committee will be mindful of equality considerations when assessing subgroups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

No changes were made to the scope. The committee will consider all potential equality issues during the appraisal process.
--

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

No additional stakeholders related to potential equality issues were added.

Approved by Associate Director (name): Jasdeep Hayre **Date:** 20 November 2023